PwPepwise

Kisspeptin-10

Sex & Libido

a.k.a. KP-10

Upstream GnRH regulator

Kisspeptin-10 is a naturally occurring signaling peptide derived from the KiSS-1 gene.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Reproductive hormone stimulation in men (IV bolus)1 μg/kg—SubcutaneousInjected just under the skin, into the fat layer.—
Continuous IV infusion in men1.5 μg/kg—SubcutaneousInjected just under the skin, into the fat layer.—
Equine reproductive model50 μg—SubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Kisspeptin-10 is a naturally occurring signaling peptide derived from the KiSS-1 gene, representing the biologically active ten-amino-acid core of a larger family of kisspeptin molecules. It acts primarily in the brain to trigger the release of reproductive hormones, making it a key regulator of the hormonal cascade that governs fertility, puberty, and sexual function in both sexes. By activating its receptor (GPR54/KISS1R) on specialized neurons in the hypothalamus, kisspeptin-10 stimulates the release of gonadotropin-releasing hormone (GnRH), which in turn drives the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland5,7.

In human studies, kisspeptin-10 has been reported to stimulate LH and testosterone release in men at relatively low doses, and may stimulate gonadotropin release in women during specific phases of the menstrual cycle1,14. Beyond reproduction, the peptide appears to play roles in regulating prolactin secretion19, modulating growth hormone release12,20, and influencing vascular tone16. It has also been identified as a physiological regulator of trophoblast invasion during early pregnancy8. Research into its therapeutic potential across reproductive medicine and related fields is actively expanding.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Kisspeptin-10 (Kp-10) is the biologically active C-terminal decapeptide fragment of the KiSS-1 gene product, sharing the conserved RF-amide motif essential for receptor binding. It is the minimal sequence required for full agonist activity at GPR54 (also designated KISS1R), a Gq/11-coupled seven-transmembrane receptor5,7. Upon GPR54 activation, the primary intracellular signaling cascade involves phospholipase C (PLC) activation, generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), mobilization of intracellular calcium stores, and activation of protein kinase C (PKC)15,20. Downstream, ERK1/2 and p38 MAPK recruitment have been identified as required effectors for GnRH secretion, while mTOR and PI3K pathways selectively mediate LH — but not GH — release from primate pituitary cells, indicating pathway bifurcation at the receptor level15,20.

The primary neuroendocrine site of action is the hypothalamic arcuate nucleus (ARC), where kisspeptin-10 administration increases GnRH pulse generator frequency; antagonist studies confirm that ARC — but not the medial preoptic area — is required for tonic pulsatile LH regulation11. Kisspeptin-10 acts on GnRH-1 neurons by facilitating a plasma membrane-driven calcium oscillator, increasing spike frequency in already-oscillating cells and initiating oscillations in quiescent cells through TTX-sensitive sodium channels and nonselective cationic channels, with IP3 receptor-operated channels playing a secondary role17. This mechanism does not require COX-2 or prostaglandin synthesis15. Hypothalamic LHRH/GnRH release is the obligatory intermediary for gonadotropin stimulation, as pituitary fragments are unresponsive to kisspeptin-10 in vitro at concentrations up to 1000 nM7, though direct pituitary effects via locally expressed GPR54 have been characterized in dispersed rat and baboon pituitary cell preparations, with maximal LH release at approximately 10 nM and selectivity for gonadotrophs and somatotrophs over other pituitary cell types12,20.

Kisspeptin-10 also inhibits hypothalamic tuberoinfundibular dopaminergic neurons, reducing median eminence DOPAC concentrations and thereby disinhibiting prolactin release in an estradiol-dependent manner19. In peripheral vascular tissue, GPR54 is expressed in smooth muscle of neural crest-derived vessels (aorta, coronary artery) and mesodermal umbilical vein; Kp-10 acts as a potent vasoconstrictor with high-affinity binding (KD ~0.2 nM) and pEC50 values of approximately 7.9–8.4 in isolated human vessel preparations16. The responsiveness of the HPG axis to kisspeptin-10 is dynamically regulated by gonadal steroid milieu — estradiol potentiates LH responses at both hypothalamic and pituitary levels13,20 — and by reproductive state, with sensitivity varying across the estrous cycle, pregnancy, and lactation13.

§04Evidence & efficacy

Evidence base
340Studies
118Human
111Animal

Kisspeptin-10 consistently stimulates LH and FSH release through GnRH-dependent mechanisms across multiple animal species and in early human studies, establishing a well-replicated preclinical mechanistic profile5,7,9,13,18. In rodents, peripheral IV administration stimulates LH secretion dose-dependently from doses as low as 0.3 nmol/kg, and repeated dosing produces consistent LH pulses without tachyphylaxis18. In non-human primates, hourly IV pulses of 2 μg over 48 hours sustained pulsatile LH discharges mimicking pubertal GnRH release patterns9.

In human men, kisspeptin-10 appears to stimulate LH and FSH release at IV bolus doses of 0.3–1.0 nmol/kg, and continuous IV infusion at 4 μg/kg·h may elevate testosterone by approximately 45%1,14. In women, gonadotropin stimulation appears to be restricted to the preovulatory phase of the menstrual cycle, with no response observed during the follicular phase regardless of dose or route1.

Beyond reproductive endocrinology, kisspeptin-10 appears to potentiate glucose-stimulated insulin secretion from human, porcine, rat, and mouse islets in a reversible, concentration-dependent manner3, and may regulate prolactin secretion via hypothalamic dopaminergic inhibition in an estradiol-dependent fashion19. It has also been reported to inhibit trophoblast migration and invasion in ex vivo human placental tissue8, and may directly stimulate growth hormone release from primate pituitary cells20.

In a small equine RCT, continuous kisspeptin-10 infusion significantly accelerated ovarian response and increased LH in seasonally anovulatory mares compared to saline controls4.

§05Safety

Across all published human studies, kisspeptin-10 administration via IV bolus and continuous IV infusion — including prolonged infusions lasting up to 22.5 hours — appears to have been well tolerated, with no adverse events explicitly reported in the available study records1,14. Multiple routes have been evaluated in women (IV bolus, SC bolus, IV infusion) at a wide range of doses, also without reported adverse events1.

A pharmacodynamically relevant observation is the bell-shaped dose-response curve for LH stimulation, where supraphysiological IV bolus doses (3 μg/kg) produced a blunted LH response compared to lower doses (1 μg/kg), consistent with receptor desensitization at high concentrations14. This is a functional rather than toxicological finding but has practical relevance for dosing.

Kisspeptin-10 is a potent vasoconstrictor in isolated human coronary artery and umbilical vein preparations, acting via GPR54 receptors expressed in vascular smooth muscle of atherosclerosis-prone vessels16. This represents an observed biological signal in ex vivo human tissue that ongoing research will help characterize in clinical context.

No long-term safety data, drug interaction information, or formal Phase 1 dose-escalation safety reports are available in the current evidence base. Human safety characterization is an active area of clinical investigation.

§06History

The KiSS-1 gene was originally identified in 1996 as a metastasis-suppressor gene in human melanoma, and its protein product was subsequently termed metastin or kisspeptin-54. The discovery of GPR54 (KISS1R) as the cognate receptor, and the characterization of loss-of-function mutations causing idiopathic hypogonadotropic hypogonadism in humans and mice, established the kisspeptin-GPR54 axis as an essential regulator of reproductive function in the early 2000s. Kisspeptin-10, the minimal bioactive C-terminal decapeptide, was characterized as retaining full agonist potency at GPR54.

Two landmark 2004 studies rapidly shaped the field: peripheral and central administration of kisspeptin-10 was shown to dose-dependently stimulate LH, FSH, and testosterone through hypothalamic LHRH release in rodents7, and kisspeptin-54 was shown to stimulate gonadotropins at femtomolar ICV doses in mice with effects blocked by GnRH antagonism5. The same year, kisspeptin-10 was identified as a physiological inhibitor of trophoblast invasion in human placental tissue, expanding the biology beyond reproductive neuroendocrinology8.

By 2005–2006, primate studies confirmed the role of kisspeptin-GPR54 signaling in puberty initiation6,9, and the arcuate nucleus was established as the primary anatomical locus for GnRH pulse generation by kisspeptin11. The first human studies demonstrating gonadotropin stimulation in men and women appeared around 20111,14, initiating translational investigation into therapeutic applications in hypogonadism, infertility, and related reproductive disorders. Research into metabolic, cardiovascular, and placental roles of kisspeptin-10 continues to expand the therapeutic landscape.

§07References